Journal Article (Letter)

DKFZ-2024-00082

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold.

Schmäche, T. ; Fohgrub, J. ; Klimova, A. ; Laaber, K.DKFZ* ; Drukewitz, S. ; Merboth, F. ; Hennig, A. ; Seidlitz, T. ; Herbst-Nowrouzi, F.DKFZ* ; Baenke, F. ; Ada, A.-M. ; Groß, T.DKFZ* ; Wenzel, C. ; Ball, C.DKFZ* ; Praetorius, C. ; Schmidt, T. ; Ringelband-Schilling, B. ; Koschny, R. ; Stenzinger, A. ; Roeder, I. ; Jäger, D.DKFZ* ; Zeissig, S. ; Welsch, T. ; Aust, D. ; Glimm, H.DKFZ* ; Folprecht, G. ; Weitz, J. ; Haag, G. M. (Last author)DKFZ* ; Stange, D. E.

2024
Biomed Central London

This record in other databases:  

Please use a persistent id in citations: doi:10.1186/s12943-023-01919-3

Abstract: This study sought to determine the value of patient-derived organoids (PDOs) from esophago-gastric adenocarcinoma (EGC) for response prediction to neoadjuvant chemotherapy (neoCTx).Endoscopic biopsies of patients with locally advanced EGC (n = 120) were taken into culture and PDOs expanded. PDOs' response towards the single substances of the FLOT regimen and the combination treatment were correlated to patients' pathological response using tumor regression grading. A classifier based on FLOT response of PDOs was established in an exploratory cohort (n = 13) and subsequently confirmed in an independent validation cohort (n = 13).EGC PDOs reflected patients' diverse responses to single chemotherapeutics and the combination regimen FLOT. In the exploratory cohort, PDOs response to single 5-FU and FLOT combination treatment correlated with the patients' pathological response (5-FU: Kendall's τ = 0.411, P = 0.001; FLOT: Kendall's τ = 0.694, P = 2.541e-08). For FLOT testing, a high diagnostic precision in receiver operating characteristic (ROC) analysis was reached with an AUCROC of 0.994 (CI 0.980 to 1.000). The discriminative ability of PDO-based FLOT testing allowed the definition of a threshold, which classified in an independent validation cohort FLOT responders from non-responders with high sensitivity (90%), specificity (100%) and accuracy (92%).In vitro drug testing of EGC PDOs has a high predictive accuracy in classifying patients' histological response to neoadjuvant FLOT treatment. Taking into account the high rate of successful PDO expansion from biopsies, the definition of a threshold that allows treatment stratification paves the way for an interventional trial exploring PDO-guided treatment of EGC patients.

Keyword(s): Gastric cancer ; Patient-derived organoids ; Personalized medicine ; Response prediction

Note: #LA:D120# / Correspondence

---

Contributing Institute(s):

1. B280 Translationale funktionelle Krebsgenomik (B280)
2. DKTK Koordinierungsstelle Dresden (DD01)
3. D120 Angewandte Tumor-Immunität (D120)

Research Program(s):

1. 314 - Immunologie und Krebs (POF4-314) (POF4-314)

Appears in the scientific report 2024

---

Database coverage:
; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 30 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---